{"id":"high-dose-oliceridine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oliceridine binds to mu-opioid receptors and preferentially activates G-protein coupled signaling over beta-arrestin pathways, which may reduce some opioid-related adverse effects compared to traditional mu-opioid agonists. This biased signaling approach aims to maintain analgesic efficacy while potentially decreasing respiratory depression, constipation, and other side effects associated with conventional opioids.","oneSentence":"Oliceridine is a mu-opioid receptor agonist that selectively activates G-protein signaling pathways to provide analgesia with potentially reduced beta-arrestin signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:39:59.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe acute pain in adults"}]},"trialDetails":[{"nctId":"NCT06320041","phase":"PHASE4","title":"Efficacy and Safety of Oliceridine for Moderate to Severe Acute Pain After Orthopedic Surgery","status":"RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2024-08-01","conditions":"Postoperative Pain","enrollment":162},{"nctId":"NCT06409689","phase":"NA","title":"Oliceridine-Enhanced Analgesia and Recovery: A G-Protein Biased μ-Opioid Study","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-06-01","conditions":"Postoperative Analgesia","enrollment":80},{"nctId":"NCT06619145","phase":"PHASE4","title":"1.Comparison of the Analgesic Effect of Remifentanil Group and Different Dose Groups of Oliceridine in Postoperative Patients Undergoing Cardiac Surgery 2.Exploring the Hemodynamic Effects of Analgesic Regimens With Different Doses of Oliceridine After Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-11-01","conditions":"Oliceridine, Postoperative Cardiac Surgery","enrollment":270}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"High dose Oliceridine","genericName":"High dose Oliceridine","companyName":"Nanjing First Hospital, Nanjing Medical University","companyId":"nanjing-first-hospital-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oliceridine is a mu-opioid receptor agonist that selectively activates G-protein signaling pathways to provide analgesia with potentially reduced beta-arrestin signaling. Used for Moderate to severe acute pain in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}